Skip to Main Content

OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Overactive Bladder in Pediatric Patients

Conditions

Children's Health | Diseases of the Kidney & Urinary Tract

Phase III

What is the purpose of this trial?

This study will evaluate the safety and efficacy of onabotulinumtoxinA (BOTOX®) for the treatment of urinary incontinence due to overactive bladder in pediatric patients between the ages of 12 to 17 years who have not been adequately managed with anticholinergics.

  • Trial with
    Allergan Sales, Inc.
  • Start Date
    01/01/2015
  • End Date
    12/30/2018
Trial Image

For more information about this study, contact:

Kristin DeFrancesco

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    02/22/2018
  • Study HIC
    #1409014633